Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y; Japanese Urological Oncology Group. Matsuda A, et al. Among authors: yasue k. BJU Int. 2024 Aug;134(2):207-218. doi: 10.1111/bju.16296. Epub 2024 Feb 12. BJU Int. 2024. PMID: 38344879
How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Urabe F, Kimura T, Sasaki H, Tashiro K, Iwatani K, Yasue K, Aoki M, Sato S, Takahashi H, Miki K, Egawa S. Urabe F, et al. Among authors: yasue k. Int J Clin Oncol. 2022 Jan;27(1):184-193. doi: 10.1007/s10147-021-02040-5. Epub 2021 Oct 2. Int J Clin Oncol. 2022. PMID: 34599724 Clinical Trial.
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Miyajima K, Suzuki H, Urabe F, Iwatani K, Imai Y, Yasue K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Koike Y, Miki J, Yuen S, Sasaki T, Aoki M, Sato S, Takahashi H, Miki K, Kimura T. Miyajima K, et al. Among authors: yasue k. Int J Clin Oncol. 2023 Sep;28(9):1200-1206. doi: 10.1007/s10147-023-02383-1. Epub 2023 Jul 11. Int J Clin Oncol. 2023. PMID: 37432614
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, Hata K, Murakami M, Koike Y, Miki J, Yamada H, Kimura T. Shimomura T, et al. Among authors: yasue k. Int J Clin Oncol. 2024 Feb;29(2):213-221. doi: 10.1007/s10147-023-02441-8. Epub 2023 Dec 16. Int J Clin Oncol. 2024. PMID: 38103156
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Narita C, Urabe F, Fukuokaya W, Iwatani K, Imai Y, Yasue K, Mori K, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Yuen SKK, Teoh JY, Shimomura T, Yamada H, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Narita C, et al. Among authors: yasue k. Clin Genitourin Cancer. 2024 Jun;22(3):102082. doi: 10.1016/j.clgc.2024.102082. Epub 2024 Mar 21. Clin Genitourin Cancer. 2024. PMID: 38641443
Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world.
Shimomura T, Mori K, Ito K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, Hata K, Murakami M, Koike Y, Miki J, Yamada H, Kimura T. Shimomura T, et al. Among authors: yasue k. Int Urol Nephrol. 2024 Dec;56(12):3719-3725. doi: 10.1007/s11255-024-04116-3. Epub 2024 Jun 24. Int Urol Nephrol. 2024. PMID: 38913290
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomes.
Saito S, Takahashi H, Yata Y, Takamizawa S, Hara S, Miyajima K, Iwatani K, Yasue K, Nishikawa H, Yamamoto T, Koide H, Sadakane I, Atsuta M, Mori K, Imai Y, Kayano S, Murakami M, Tashiro K, Tsuzuki S, Yamada H, Miki J, Urabe F, Kimura T, On Behalf Of Jikei-Scrum Collaborative Group. Saito S, et al. Among authors: yasue k. Jpn J Clin Oncol. 2024 Nov 2;54(11):1201-1207. doi: 10.1093/jjco/hyae081. Jpn J Clin Oncol. 2024. PMID: 38920339
60 results